跳转至内容
Merck
所有图片(1)

Key Documents

更多文件

557502

Sigma-Aldrich

Ro-20-1724

A cell-permeable, selective inhibitor of cAMP-specific phosphodiesterase (PDE IV; IC₅₀ = 2 µM).

别名:

Ro-20-1724, 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C15H22N2O3
CAS号:
29925-17-5
分子量:
278.35
MDL號碼:
MFCD00077397
分類程式碼代碼:
12352200

品質等級

100

化驗

≥98% (TLC)

形狀

solid

製造商／商標名

Calbiochem®

儲存條件

OK to freeze

顏色

white

溶解度

DMSO: 20%
ethanol: 4%

運輸包裝

ambient

儲存溫度

10-30°C

InChI

1S/C15H22N2O3/c1-3-4-7-20-14-9-11(5-6-13(14)19-2)8-12-10-16-15(18)17-12/h5-6,9,12H,3-4,7-8,10H2,1-2H3,(H2,16,17,18)

InChI 密鑰

PDMUULPVBYQBBK-UHFFFAOYSA-N

一般說明

A cell-permeable, selective inhibitor of cAMP-specific phosphodiesterase (PDE IV; IC50 = 2 µM). Inhibits superoxide generation and arachidonic-induced platelet aggregation. Also inhibits fMLP-induced neutrophil adhesion to vascular endothelial cells.
Selective inhibitor of cAMP-specific phosphodiesterase (PDE IV, IC50 = 2 µM). Inhibits superoxide generation and arachidonic-induced platelet aggregation. Also inhibits fMLP-induced neutrophil adhesion to vascular endothelial cells.

生化／生理作用

Cell permeable: yes
Primary Target
PDE IV
Product does not compete with ATP.
Reversible: no
Target IC50: 2 µM against PDE IV

警告

Toxicity: Irritant (B)

其他說明

Derian, C.K., et al. 1995. J. Immunol. 154, 308.
Rubin, L.L., et al. 1991. J. Cell Biol.115, 1725.
Lad, P.M., et al. 1985. Biochim. Biophys. Acta 846, 286.
Bergstrand, H., et al. 1977. Mol. Pharmacol.13, 38.

法律資訊

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Mohammad Keyvanloo Shahrestanaki et al.
Research in pharmaceutical sciences, 14(2), 107-114 (2019-10-18)
Diabetes incidence showed ascending trends in recent years indicating urgent need for new therapeutic agents. Extracellular adenosine signaling showed promising results. However, role of its A3 receptor in pancreatic β-cells proliferation and insulin secretion is not well established. Thus, we
Pieter J Gaillard et al.
Methods in molecular biology (Clifton, N.J.), 437, 161-175 (2008-03-29)
Drug delivery across the blood-brain barrier (BBB) is a major obstacle for the development of effective treatments of many central nervous system disorders. Sophisticated cell culture models of the BBB have helped us to identify, characterize, and validate a novel
Alejandro Sánchez-Melgar et al.
Frontiers in neuroscience, 15, 702817-702817 (2021-09-21)
Gliomas are the most common and aggressive primary tumors in the central nervous system. The nucleoside adenosine is considered to be one major constituent within the tumor microenvironment. The adenosine level mainly depends on two enzymatic activities: 5'-nucleotidase (5'NT or

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门